Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n−3 polyunsaturated fatty acids, esp...

The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and...

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% ...

Hypertension is a frequent and early manifestation in autosomal dominant polycystic kidney disease, significantly associated with kidney function decline and cardiovascular outcomes. Autosomal dominan...

AbstractIntroduction. The ANCA Renal Risk Score was revised in 2023 to improve clinico-pathological prognostication in patients with ANCA-associated vascul

AbstractBackground. The European Kidney Function Consortium (EKFC) 2021 equation to estimate GFR performs as well or better than the CKD-EPI 2009 equation

Nature Reviews Nephrology, Published online: 21 July 2025; doi:10.1038/s41581-025-00980-zSince the discovery of PLA2R, several target antigens associated with membranous nephropathy have been identified. This Review describes the distinct clinical associations, pathology and prognostic findings associated with each of the identified target antigens and implications for the reclassification of membranous nephropathy.

The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of chronic kidney disease.

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...

To the Editor: In their letter to the Editor, Izzedine et al. (April 4 issue)1 propose the measurement of cystatin C to estimate kidney function in a patient treated with selpercatinib who had a de...